The JALSG APL92 study for newly diagnosed acute promyelocytic leukemia (APL): Analysis of prognostic factors to increase cure rate in the next study.

被引：0
|
作者：
Ohno, R [1 ]
Asou, N [1 ]
Kanamaru, A [1 ]
Miyawaki, S [1 ]
Ohtake, S [1 ]
Tomonaga, M [1 ]
机构：
[1] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 43131, Japan
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2262
引用
收藏
页码：505A / 505A
页数：1
相关论文
共 47 条
  • [1] Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG)
    Norio Asou
    Koichi Adachi
    Jun-ichi Tamura
    Akihisa Kanamaru
    Shin-ichi Kageyama
    Akira Hiraoka
    Eijiro Omoto
    Hideki Akiyama
    Kazuo Tsubaki
    Kenji Saito
    Kazutaka Kuriyama
    Hakumei Oh
    Kiyoshi Kitano
    Shuichi Miyawaki
    Kunihiko Takeyama
    Osamu Yamada
    Kiyoshi Nishikawa
    Masatomo Takahashi
    Shin Matsuda
    Shigeki Ohtake
    Ryuzo Ohno
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S65 - S71
  • [2] Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG)
    Asou, N
    Adachi, K
    Tamura, J
    Kanamaru, A
    Kageyama, S
    Hiraoka, A
    Omoto, E
    Akiyama, H
    Tsubaki, K
    Saito, K
    Kuriyama, K
    Oh, H
    Kitano, K
    Miyawaki, S
    Takeyama, K
    Yamada, O
    Nishikawa, K
    Takahashi, M
    Matsuda, S
    Ohtake, S
    Ohno, R
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S65 - S71
  • [3] A Phase III Study of New Synthetic Retinoid Tamibarotene(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study
    Shinagawa, Katsuji
    Ohtake, Shigeki
    Sakura, Toru
    Ueda, Yasunori
    Sawa, Masashi
    Miyatake, Jun-ichi
    Usui, Noriko
    Onitsuka, Makoto
    Hatta, Yoshihiro
    Emi, Nobuhiko
    Tamaki, Shigehisa
    Ito, Yoshikazu
    Murayama, Toru
    Fujita, Hiroyuki
    Fujimaki, Katsumichi
    Asou, Norio
    Takeshita, Akihiro
    Miyazaki, Yasushi
    Miyawaki, Shuichi
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2012, 120 (21)
  • [4] Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) results of a randomized study.
    de Botton, S
    Coitteux, V
    Chevret, S
    Dombret, H
    Sanz, M
    San Miguel, J
    Caillot, D
    Vekhof, A
    Gardembas, M
    Stamatoullas, A
    Condé, E
    Guerci, A
    Gardin, C
    Fey, M
    Jacky, E
    Makhoul, DC
    Reman, O
    de la Serna, J
    Lefrere, F
    Chomienne, C
    Degos, L
    Fenaux, P
    BLOOD, 2001, 98 (11) : 766A - 766A
  • [5] JALSG-AML92 for newly diagnosed acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) followed by intensive consolidation acid maintenance/intensification chemotherapy: Prognostic factors for remission and survival
    Ohno, R
    Asou, N
    Kanamaru, A
    Adachi, K
    Miyawaki, S
    Kageyama, S
    Hiraoka, A
    Ohmoto, E
    Sakamaki, H
    Tsubaki, K
    Saito, K
    Kuriyama, K
    Oh, H
    Kitano, Y
    BLOOD, 1996, 88 (10) : 1157 - 1157
  • [6] CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study
    Takeshita, Akihiro
    Asou, Norio
    Atsuta, Yoshiko
    Furumaki, Hiroaki
    Sakura, Toru
    Ueda, Yasunori
    Sawa, Masashi
    Dobashi, Nobuaki
    Suzuki, Rikio
    Taniguchi, Yasuhiro
    Nakagawa, Masaru
    Tamaki, Shigehisa
    Hagihara, Maki
    Fujimaki, Katsumichi
    Yokoyama, Yasuhisa
    Fujita, Hiroyuki
    Yanada, Masamitsu
    Maeda, Yoshinobu
    Usui, Noriko
    Kobayashi, Yukio
    Kiyoi, Hitoshi
    Ohtake, Shigeki
    Matsumura, Itaru
    Naoe, Tomoki
    Miyazaki, Yasushi
    BLOOD, 2018, 132
  • [7] Prognostic Impact of Chromosomal Variation in Patients with Acute Promyelocytic Leukemia (APL); Analysis of 775 Cases Enrolled in the Japan Adult Leukemia Study Group APL Studies
    Adachi, Miwa
    Takeshita, Akihiro
    Taki, Tomohiko
    Ohtake, Shigeki
    Shinagawa, Katsuji
    Kiyoi, Hitoshi
    Matsuda, Mitsuhiro
    Takahashi, Masatomo
    Emi, Nobuhiko
    Kobayashi, Yukio
    Miyamura, Koichi
    Fujita, Hiroyuki
    Sakura, Toru
    Iwanaga, Masako
    Usui, Noriko
    Miyawaki, Shuichi
    Asou, Norio
    Ohnishi, Kazunori
    Miyazaki, Yasushi
    Naoe, Tomoki
    BLOOD, 2014, 124 (21)
  • [8] Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
    Ades, Lionel
    Thomas, Xavier
    Bresler, Agnes Guerci
    Raffoux, Emmanuel
    Spertini, Olivier
    Vey, Norbert
    Marchand, Tony
    Recher, Christian
    Pigneux, Arnaud
    Girault, Stephane
    Deconinck, Eric
    Gardin, Claude
    Tournilhac, Olivier
    Lambert, Jean Francois
    Chevallier, Patrice
    de Botton, Stephane
    Lejeune, Julie
    Dombret, Herve
    Chevret, Sylvie
    Fenaux, Pierre
    HAEMATOLOGICA, 2018, 103 (12) : 2033 - 2039
  • [9] Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA
    Ades, Lionel
    Montesinos, Pau
    Chevret, Sylvie
    Vellenga, Edo
    Raffoux, Emmanuel
    Rayon, Chelo
    Diaz-Mediavilla, Joaquim
    Thomas, Xavier
    Chevallier, Patrice
    Rivas, Concha
    Guerci, Agnes
    Amutio, Elena
    Huguet, Francoise
    Arias, Jesus
    Vey, Norbert
    Deben, Guillermo
    Meyer, Sandrine
    Novo, Andres
    Ferrant, Augustin
    Bergua, Juan
    Rigon, Mathieu Resche
    de la Serna, Javier
    Dombret, Herve
    Castaigne, Sylvie
    Fenaux, Pierre
    Sanz, Miguel A.
    BLOOD, 2009, 114 (22) : 348 - 348
  • [10] Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group
    C Callens
    S Chevret
    J-M Cayuela
    B Cassinat
    E Raffoux
    S de Botton
    X Thomas
    A Guerci
    N Fegueux
    A Pigneux
    A-M Stoppa
    T Lamy
    F Rigal-Huguet
    A Vekhoff
    S Meyer-Monard
    A Ferrand
    M Sanz
    C Chomienne
    P Fenaux
    H Dombret
    Leukemia, 2005, 19 : 1153 - 1160
12345